Quarterly report pursuant to Section 13 or 15(d)

Condensed Consolidated Statements of Cash Flows (Unaudited)

v3.22.2.2
Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($)
$ in Thousands
9 Months Ended
Sep. 30, 2022
Sep. 30, 2021
Cash Flows From Operating Activities    
Net loss $ (20,394) $ (11,214)
Adjustments to reconcile net loss to net cash used in operating activities:    
Depreciation and amortization 2,206 4,350
Interest accretion expense 123 375
Bad debt recovery (140)
Mark to market on warrants (71) 137
Goodwill impairment 8,433
Intangible asset impairment 3,827
Amortization of deferred financing fees 45 110
Interest - note payable 372
Stock-based compensation 1,133 1,228
ESPP expense 46 86
Change in fair value of note payable 46
Change in fair value of contingent consideration (311) (57)
Gain on DiamiR transaction (235)
Other gains and expenses, net (2)
Changes in operating assets and liabilities:    
Accounts receivable 107 1,788
Other current assets (45) (413)
Other long-term assets (1) (14)
Accounts payable (447) (2,084)
Accrued salaries and bonus (1,312) (433)
Accrued liabilities (914) (1,349)
Long-term liabilities 113 (6)
Net cash used in operating activities (7,416) (7,501)
Cash Flows From Investing Activity    
Proceeds from sale of Interpace Pharma Solutions, net 7,431
Purchase of property and equipment (126) (192)
Sale of property and equipment 39
Net cash provided by (used in) investing activities 7,305 (153)
Cash Flows From Financing Activities    
Issuance of common stock, net of expenses 106 335
Loan proceeds - related parties 7,500
Financing fees - related party (123)
Proceeds from notes payable 2,000
Borrowings on line of credit 1,000
Net cash provided by financing activities 3,106 7,712
Net increase in cash, cash equivalents and restricted cash 2,995 58
Cash, cash equivalents and restricted cash from continuing operations– beginning 2,922 1,236
Cash, cash equivalents and restricted cash from discontinued operations– beginning 392 2,136
Cash, cash equivalents and restricted cash – beginning 3,314 3,372
Cash, cash equivalents and restricted cash from continuing operations– ending 6,309 2,916
Cash, cash equivalents and restricted cash from discontinued operations– ending 514
Cash, cash equivalents and restricted cash – ending $ 6,309 $ 3,430